However, broader application of current ICIs, including anti‐PD‐1, anti‐PD‐L1 and anti‐CTLA‐4 mAbs, is limited by primary or acquired resistance such that only a fraction of cancer patients shows durable benefit. Here, PDCD1 is linked to cancer.